GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Dova Pharmaceuticals Inc (NAS:DOVA) » Definitions » Operating Income

Dova Pharmaceuticals (Dova Pharmaceuticals) Operating Income : $-72.99 Mil (TTM As of Sep. 2019)


View and export this data going back to 2017. Start your Free Trial

What is Dova Pharmaceuticals Operating Income?

Dova Pharmaceuticals's Operating Income for the three months ended in Sep. 2019 was $-20.67 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Sep. 2019 was $-72.99 Mil.

Operating Margin % is calculated as Operating Income divided by its Revenue. Dova Pharmaceuticals's Operating Income for the three months ended in Sep. 2019 was $-20.67 Mil. Dova Pharmaceuticals's Revenue for the three months ended in Sep. 2019 was $3.37 Mil. Therefore, Dova Pharmaceuticals's Operating Margin % for the quarter that ended in Sep. 2019 was -612.66%.

Dova Pharmaceuticals's 5-Year average Growth Rate for Operating Margin % was 0.00% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Dova Pharmaceuticals's annualized ROC % for the quarter that ended in Sep. 2019 was -1,841.18%. Dova Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2019 was -4,940.75%.


Dova Pharmaceuticals Operating Income Historical Data

The historical data trend for Dova Pharmaceuticals's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dova Pharmaceuticals Operating Income Chart

Dova Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18
Operating Income
- -29.21 -71.05

Dova Pharmaceuticals Quarterly Data
Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19
Operating Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -19.32 -19.05 -16.35 -16.93 -20.67

Dova Pharmaceuticals Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Sep. 2019 adds up the quarterly data reported by the company within the most recent 12 months, which was $-72.99 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Dova Pharmaceuticals  (NAS:DOVA) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Dova Pharmaceuticals's annualized ROC % for the quarter that ended in Sep. 2019 is calculated as:

ROC % (Q: Sep. 2019 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2019 ) + Invested Capital (Q: Sep. 2019 ))/ count )
=-82.66 * ( 1 - 0% )/( (5.003 + 3.976)/ 2 )
=-82.66/4.4895
=-1,841.18 %

where

Note: The Operating Income data used here is four times the quarterly (Sep. 2019) data.

2. Joel Greenblatt's definition of Return on Capital:

Dova Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2019 is calculated as:

ROC (Joel Greenblatt) %(Q: Sep. 2019 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2019  Q: Sep. 2019
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-81.72/( ( (1.583 + max(-4.858, 0)) + (1.725 + max(-4.184, 0)) )/ 2 )
=-81.72/( ( 1.583 + 1.725 )/ 2 )
=-81.72/1.654
=-4,940.75 %

where Working Capital is:

Working Capital(Q: Jun. 2019 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(3.154 + 4.167 + 1.496) - (11.755 + 1.92 + 0)
=-4.858

Working Capital(Q: Sep. 2019 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1.244 + 4.683 + 2.85) - (12.961 + 0 + 0)
=-4.184

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Sep. 2019) EBIT data.

3. Operating Income is also linked to Operating Margin %:

Dova Pharmaceuticals's Operating Margin % for the quarter that ended in Sep. 2019 is calculated as:

Operating Margin %=Operating Income (Q: Sep. 2019 )/Revenue (Q: Sep. 2019 )
=-20.665/3.373
=-612.66 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.


Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Dova Pharmaceuticals Operating Income Related Terms

Thank you for viewing the detailed overview of Dova Pharmaceuticals's Operating Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Dova Pharmaceuticals (Dova Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
240 Leigh Farm Road, Suite 245, Durham, NC, USA, 27707
Dova Pharmaceuticals Inc is a United States based clinical-stage pharmaceutical company engaged in developing treatments for patients suffering from orphan diseases. It is focused on acquiring, developing and commercializing drug candidates for diseases that are treated by specialist physicians, with an initial focus on addressing thrombocytopenia, a disorder characterized by a low blood platelet count. The company's drug candidate, avatrombopag, is an orally administered thrombopoietin receptor agonist, or TPO-RA, that it is developing for the treatment of thrombocytopenia. The company's drug candidate, avatrombopag, is designed to mimic the effects of thrombopoietin, in vitro and in vivo. Thrombopoietin is a hormone produced in the liver and kidney that binds to its receptor.
Executives
Nancy Wysenski director 2200 SUNBURST STREET, CHATSWORTH CA 90401
Joseph Edelman 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Perceptive Advisors Llc 10 percent owner 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Perceptive Life Sciences Master Fund Ltd 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Allen Lee F Md Phd officer: Chief Medical Officer C/O AMAG PHARMACEUTICALS, INC., 125 CAMBRIDGEPARK DRIVE, 6TH FLOOR, CAMBRIDGE MA 02140
Roger Jeffs director
Alfred J Novak director 325 NE 6TH ST, BOCA RATON FL 33432
David Zaccardelli director, officer: President & CEO 300 TRI STATE INTERNATIONAL, SUITE 272, LINCOLNSHIRE IL 60069
Paul B Manning director, 10 percent owner 200 GARRETT STREET SUITE S, CHARLOTTESVILLE VA 22902
Stalfort John A Iii director C/O ACUMEN PHARMACEUTICALS, INC., 427 PARK STREET, CHARLOTTESVILLE VA 22902
Jason Hoitt officer: Chief Commercial Officer C/O DOVA PHARMACEUTICALS, INC., 240 LEIGH FARM ROAD, SUITE 245, DURHAM NC 27707
Alex Sapir director, officer: President & CEO C/O DOVA PHARMACEUTICALS, INC., 240 LEIGH FARM ROAD, SUITE 245, DURHAM NC 27707

Dova Pharmaceuticals (Dova Pharmaceuticals) Headlines

From GuruFocus